In his weekly clinical update, Dr. Griffin discusses modeling poliovirus transmission and responses in New York State, FDA approves first vaccine for pregnant individuals to prevent RSV in infants, prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices, Nirmatrelvir resistance – de novo E166V/L50V mutations in an immunocompromised patient treated with prolonged nirmatrelvir/ritonavir monotherapy leading to clinical and virological treatment failure, incidence of new-onset hypertension post–COVID-19: comparison with influenza, and post-acute sequelae of COVID-19 at 2 years.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Modeling poliovirus transmission and responses in New York State (JID)
• FDA approves first vaccine for pregnant individuals to prevent RSV in infants (FDA)
• Prevention and control of seasonal influenza with vaccines (CDC)
• De novo E166V/L50V mutations in an immunocompromised patient treated with nirmatrelvir/ritonavir (CID)
• Incidence of new-onset hypertension post–COVID-19 (Hypertension)
• Postacute sequelae of COVID-19 at 2 years (Nature Medicine)
• Contribute to our Floating Doctors fundraiser at PWB
• Letters read on TWiV 1038
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [email protected]